Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and obesity drugs Ozempic and ...

Novo Nordisk reported forecast-beating quarterly sales of its popular Wegovy weight-loss drug on Wednesday, sending its ...

Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, ...

Are you a print subscriber? Activate your account. By Garett Sloane - 3 min 8 sec ago By Ewan Larkin - 8 min 31 sec ago By ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem ...